non-Hodgkin lymphoma Archives -

Market Access/ News/ News/ News/ Oncology

CHMP backs Roche’s lymphoma bispecific mosunetuzumab

Phil Taylor CHMP, immuno-oncology, mosunetuzumab, non-Hodgkin lymphoma, Non-small cell lung cancer, Oncology, Roche, Tecentriq 0 Comment

Roche is on the brink of its first regulatory approval for what could be the first bispecific antibody

CHMP backs Roche’s lymphoma bispecific mosunetuzumab

https://pharmaphorum.com/news/chmp-backs-roches-lymphoma-bispecific-mosunetuzumab/

News/ News/ Oncology

AACR: Affimed builds case for natural killer cell therapy

Phil Taylor Affimed, bispecific antibody, classical Hodgkin lymphoma, immuno-oncology, natural killer cell, non-Hodgkin lymphoma, Oncology 0 Comment

Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13

AACR: Affimed builds case for natural killer cell therapy

https://pharmaphorum.com/news/aacr-affimed-builds-case-for-natural-killer-cell-therapy/

News/ News/ Oncology

Roche closes in on first-line use for lymphoma drug Polivy in Europe

Phil Taylor antibody-drug conjugate, diffuse B-Cell lymphoma, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, Roche 0 Comment

Roche has moved a step closer to extending the use of its B-cell lymphoma therapy Polivy into the

Roche closes in on first-line use for lymphoma drug Polivy in Europe

https://pharmaphorum.com/news/roche-closes-in-on-first-line-use-for-lymphoma-drug-polivy-in-europe/

News/ News/ Oncology

ASH: Trial backs Gilead’s Yescarta CAR-T in first-line lymphoma

Phil Taylor CAR-T therapies, Gilead Sciences, immuno-oncology, non-Hodgkin lymphoma, Oncology, Yescarta 0 Comment

Gilead Sciences has taken a big step towards positioning its CAR-T therapy Yescarta as an option for previously-untreated

ASH: Trial backs Gilead’s Yescarta CAR-T in first-line lymphoma

https://pharmaphorum.com/news/ash-trial-backs-gileads-yescarta-car-t-in-first-line-lymphoma/

News/ News/ Oncology

ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma

Phil Taylor Breyanzi, Bristol-Myers Squibb, Gilead Sciences, immuno-oncology, non-Hodgkin lymphoma, Oncology, Yescarta 0 Comment

A pair of trials have suggested that CAR-T therapies could offer an improved option for patients with large

ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma

https://pharmaphorum.com/news/ash-gilead-bms-car-ts-square-off-in-relapsed-lymphoma/

News/ News/ Oncology

ASH abstract drop backs Roche’s Polivy in first-line lymphoma

Phil Taylor antibody-drug conjugate, DLBCL, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, Roche 0 Comment

Roche trumpeted a top-line results of the POLARIX trial of its Polivy therapy in previously-untreated B-cell lymphoma, and

ASH abstract drop backs Roche’s Polivy in first-line lymphoma

https://pharmaphorum.com/news/ash-abstract-drop-backs-roches-polivy-in-first-line-lymphoma/

News/ News/ Oncology

Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU

Phil Taylor CAR-T therapies, EU, Incyte, MorphoSys, non-Hodgkin lymphoma, regulatory approval, tafasitamab 0 Comment

Incyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative

Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU

https://pharmaphorum.com/news/incyte-morphosys-car-t-rival-tafasitamab-approved-in-eu/

News/ News/ Oncology

Novartis’ bid to extend Kymriah into earlier use hits a roadblock

Phil Taylor CAR-T therapies, diffuse B-Cell lymphoma, immuno-oncology, Kymriah, non-Hodgkin lymphoma, Novartis, Oncology 0 Comment

Novartis’ CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few

Novartis’ bid to extend Kymriah into earlier use hits a roadblock

https://pharmaphorum.com/news/novartis-bid-to-extend-kymriah-into-earlier-use-hits-a-roadblock/

News/ News/ Oncology

Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCL

Phil Taylor antibody-drug conjugate, DLBCL, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, Roche 0 Comment

Roche has the results it was hoping for in a phase 3 trial of Polivy in newly diagnosed

Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCL

https://pharmaphorum.com/news/armed-with-ph3-trial-roche-preps-filing-for-polivy-in-first-line-dlbcl/

Trending

non-Hodgkin lymphoma

Login